---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-091170"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2024-10-28T23:59:59+00:00"
generated_at: "2026-05-30T09:45:06.510940+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# INmune Bio to host Nov 7 webinar on EMACC cognitive tool for Alzheimer's trials

## Summary
- Webinar on Nov 7, 2024 at 1 PM ET, titled "Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer's Trials."
- Poster on EMACC sensitivity and performance in Phase II Alzheimer's trial presented at CTAD2024.
- Company is conducting a Phase II trial of XPro in early AD using EMACC and CDR-SB as endpoints.
- No financial results, clinical data readouts, or material business changes disclosed.

## SEC filing metadata
- accession: 0001213900-24-091170
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2024-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390024091170/0001213900-24-091170-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390024091170/ea0218711-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-091170
- JSON: https://secwatch.observer/filing/0001213900-24-091170.json
- Plain text: https://secwatch.observer/filing/0001213900-24-091170.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.